Tranexamic Acid in Breast Esthetic Surgery.

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators prepared a novel tranexamic acid (TXA) study designed to estimate the quantity of blood loss in patients undergoing breast esthetic surgery. This study aims to quantify blood loss during abdominoplasty with and without TXA. The central hypothesis is that TXA administration reduces blood loss and fibrinolysis in breast esthetic surgery patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Poznan University of Medical Sciences
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• women scheduled for breast esthetic surgery

• ASA 1 or 2

• age >18 and <75 years

Exclusion Criteria:

• BMI <20 or >35 kg/m2

• ASA 3 or > 3

• medical history of thromboembolism

• history of hematological disease

• treatment with aspirin 14 days before the procedure

• treatment with anticoagulants 5 days before the procedure

• epilepsy

• allergy to tranexamic acid

• coagulation disorders